LENZ Therapeutics entered this Q3 2026 report as a high-risk presbyopia bet with significant growth expectations and a bruised share price over the past three months. The stock jumped 8.7% today, yet the real story sits in the income statement. Management reported Q3 revenue of US$3.4 million and a loss of US$31.0 million, with basic earnings per share of US$0.99 in the red. For a drug launch story that trades on future prescriptions and cash burn, that mix of early sales traction and heavy losses is what the market is reacting to right now.
Love the early LENZ Therapeutics sales traction but concerned about the heavy losses and cash burn profile? Check out the list of solid balance sheet and fundamentals stocks (22 results) if you want stocks aiming for growth while starting from a stronger financial base.
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs. Q3 2025): US$3.4 million vs. US$12.5 million (revenue lower year on year)
- Net Loss (Q3 2026 vs. Q3 2025): US$31.0 million loss vs. US$16.7 million loss (deeper loss year on year)
- Basic EPS (Q3 2026 vs. Q3 2025): US$0.99 loss per share vs. US$0.59 loss per share (loss per share widened)
- Products Launched (Q3 2026 vs. Q3 2025): 1 product vs. 1 product (launch footprint unchanged year on year)
LENZ is slashing field costs to bet on TV ads and telehealth. Ask Charlie what makes LENZ so sure the consumer pivot works.
LENZ Bull Case Hinges On Consumer-Led Momentum
The bullish pitch around LENZ Therapeutics leans heavily on accelerating VIZZ uptake rather than just approval status.
"Rapid early adoption of VIZZ as a differentiated, first and only aceclidine-based presbyopia therapy, with thousands of prescribing eye care professionals and strong repeat prescribing behavior, positions LENZ for accelerating prescription growth and expanding revenue."
Q3 data gives that view some concrete wins. Management reports more than 15,000 prescribing eye care professionals, over 90% awareness, and about 75% of prescribers writing repeat scripts. Paid prescriptions and product revenue each grew roughly 50% quarter on quarter, helped by consumer marketing and telehealth. Telehealth now contributes more than half of incremental scripts.
The price and this Narrative do not agree. → Uncover what this Narrative says LENZ Therapeutics is actually worth.
LENZ Bear Case: Refill Fears Versus Early Behavior
Bears argue LENZ Therapeutics could stall if real life usage fades once the novelty wears off.
"Any real world tolerability issues, such as higher than expected rates of redness or stinging, lower than anticipated refill behavior, or emerging safety concerns, could erode doctor confidence over time and materially pressure both revenue and future earnings."
Q3 data cuts against the refill part of that worry, at least early on. E pharmacy figures show about 60% of patients buying more than a one month supply and that group averaging more than 5 packs a year. That suggests meaningful repeat use, even as heavy losses underline the unresolved cost side of the launch.
Hunt For Mispriced Growth Stories
LENZ Therapeutics just showed how early sales traction can coexist with heavy reported losses. The real opportunity is spotting companies that could be undervalued before fresh information resets expectations.
- Company 1 - 16% below our estimate - shift new manufacturing capacity toward higher value photonics programs serving AI data centers.
- Company 2 - 20% below our estimate - expand large scale facilities for cardiometabolic therapies as obesity treatments move into commercial rollout.
- Company 3 - 32% below our estimate - build AI chips and software that data center operators deploy when committing to higher power GPU focused capacity.
Three companies from the same screener. Open every one of the 30 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com